Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASH 2023 Lymphoma & CLL Highlights
Featuring presentations & discussions on selected lymphoma & CLL abstracts
from the 65th ASH Annual Meeting

25 Jan 2024 | 9am-1:30pm CST / 3-7:30pm GMT / 4-8:30pm CET

Please note that this meeting has passed – the recordings will be available on VJHemOnc soon   

Chair: John Gribben | Moderators: Petra Langerbeins, Loretta Nastoupil

*Please note: This webinar is for HCPs and allied health professionals only.
Your application to attend will be reviewed and confirmed by VJHemOnc.

Draft Agenda

9:00-9:40am CST

Lymphoma
Session 1: CAR-T                
  1. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axi-Cel As First-Line Therapy in Patients with High-Risk LBCL; (894) Julio Chavez
  2. ALLO-647 for Lymphodepletion in the Allogeneic CAR-T Setting: Safety Experience with ALLO-501/501A in Patients with R/R LBCLs and FLs;  (2095) Frederick Locke
  3. TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma; (602) Loretta Nastoupil

Live Q&A

9:40-10:15am 

Session 2: Bispecifics
  1. Subcutaneous Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma from EPCORE NHL-5; (438)  Won Seog Kim
  2. Glofitamab Monotherapy in R/R LBCL: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior CAR T-Cell Therapy and by      Baseline Total Metabolic Tumor Volume; (433) Lorenzo Falchi
  3. Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results; (858) Lorenzo Falchi 

Live Q&A

10:15-10:50am

Session 3: Bispecific Combinations
  1. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated DLBCL; (855) Adam Olszewski
  2. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed DLBCL; (856) Jason Westin
  3. Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results; (774) Yago Nieto

Live Q&A

10:50-11:20am

Session 4: BTKs
  1. Pirtobrutinib in R/R MCL Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study; (981) Jonathan Cohen
  2. Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies; (4473) Alexey Danilov

Live Q&A

11:20-11:55am

Session 5: Novel Therapies
  1. Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with R/R (R/R) Aggressive LBCL; (309) Loretta Nastoupil
  2. Efficacy and Safety of Valemetostat Monotherapy in Patients with R/R PTCLs: Primary Results of the Phase 2 VALENTINE-PTCL01 Study; (302) Steven Horwitz
  3. Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with R/R Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors; (3081) Aditi Shastri

Live Q&A

CLL

11:55am-12:35pm

Session 6: Personalized Therapy
  1. Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study; (631) Peter Hillmen
  2. Using Peripheral Blood (PB) MRD Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial; (632) Andrew Rawstron
  3. Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial; (203) Moritz Fürstenau
  4. Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with CLL/SLL with up to 5 Years of Follow-up in the Phase 2 Captivate Study; (633) Paolo Ghia

Live Q&A

12:35-1:15pm

Session 7: Novel Therapies & Combinations
  1. Liso-Cel in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004; (330) Tanya Siddiqi
  2. Combination Treatment with Sonrotoclax (BGB-11417), a 2nd-Generation BCL2 Inhibitor, and Zanubrutinib, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve CLL/SLL: (327) Chan Chea
  3. A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma; (738) Anita Kumar
  4. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial; (635) Moritz Fürstenau

Live Q&A

1:30pm CST | End of webinar

 

The Post-ASH 2023 Lymphoma & CLL Highlights has been supported by:

 

 

The content of VJHemOnc is intended for healthcare professionals